These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 30791776)

  • 1. Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn's disease?
    Ma C; Battat R; Parker CE; Khanna R; Jairath V; Feagan BG
    Expert Rev Gastroenterol Hepatol; 2019 Apr; 13(4):319-330. PubMed ID: 30791776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn's disease activity?
    Ma C; Battat R; Khanna R; Parker CE; Feagan BG; Jairath V
    Best Pract Res Clin Gastroenterol; 2019; 38-39():101602. PubMed ID: 31327404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting Endoscopic Crohn's Disease Activity Before and After Induction Therapy in Children: A Comprehensive Assessment of PCDAI, CRP, and Fecal Calprotectin.
    Zubin G; Peter L
    Inflamm Bowel Dis; 2015 Jun; 21(6):1386-91. PubMed ID: 25851564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
    Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
    World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease monitoring in inflammatory bowel disease.
    Chang S; Malter L; Hudesman D
    World J Gastroenterol; 2015 Oct; 21(40):11246-59. PubMed ID: 26523100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accurate cut-offs for predicting endoscopic activity and mucosal healing in Crohn's disease with fecal calprotectin.
    Vázquez Morón JM; Pallarés Manrique H; Machancoses FH; Ramos Lora M; Ruiz Frutos C
    Rev Esp Enferm Dig; 2017 Feb; 109(2):130-136. PubMed ID: 28071062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of disease activity of Crohn's disease through fecal calprotectin evaluated by balloon-assisted endoscopy.
    Iwamoto F; Matsuoka K; Motobayashi M; Takenaka K; Kuno T; Tanaka K; Tsukui Y; Kobayashi S; Yoshida T; Fujii T; Saito E; Yamaguchi T; Nagahori M; Sato T; Ohtsuka K; Enomoto N; Watanabe M
    J Gastroenterol Hepatol; 2018 Dec; 33(12):1984-1989. PubMed ID: 29889986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum calprotectin as a biomarker for Crohn's disease.
    Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
    J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined evaluation of fecal calprotectin and C-reactive protein as a therapeutic target in the management of patients with Crohn's disease.
    Penna FGC; Rosa RM; Pereira FH; Cunha PFS; Sousa SCS; Ferrari TCA; Cara C; Ferrari MLA
    Gastroenterol Hepatol; 2021 Feb; 44(2):87-95. PubMed ID: 32680729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utility of the assessment of fecal calprotectin in Leśniowski-Crohn's disease.
    Eder P; Stawczyk-Eder K; Krela-Kaźmierczak I; Linke K
    Pol Arch Med Wewn; 2008 Nov; 118(11):622-6. PubMed ID: 19140565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of disease location on fecal calprotectin levels in Crohn's disease.
    Gecse KB; Brandse JF; van Wilpe S; Löwenberg M; Ponsioen C; van den Brink G; D'Haens G
    Scand J Gastroenterol; 2015 Jul; 50(7):841-7. PubMed ID: 25636819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings.
    Sipponen T; Savilahti E; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
    Inflamm Bowel Dis; 2008 Jan; 14(1):40-6. PubMed ID: 18022866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fecal calprotectin is a strong predictive marker of relapse in Chinese patients with Crohn's disease: a two-year prospective study.
    Ye L; Chen BQ; Wang SD; Shi H; Yang Z; Wang FY
    Scand J Gastroenterol; 2017 Oct; 52(10):1113-1119. PubMed ID: 28675068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn's disease to assess remission and predict relapse.
    Aggarwal V; Day AS; Connor S; Leach ST; Brown G; Singh R; Friedman A; Zekry A; Craig PI
    Gastrointest Endosc; 2017 Dec; 86(6):1070-1078. PubMed ID: 28947363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal Calprotectin More Accurately Predicts Endoscopic Remission of Crohn's Disease than Serological Biomarkers Evaluated Using Balloon-assisted Enteroscopy.
    Kawashima K; Ishihara S; Yuki T; Fukuba N; Sonoyama H; Kazumori H; Yamashita N; Tada Y; Kusunoki R; Oka A; Oshima N; Mishima Y; Moriyama I; Kinoshita Y
    Inflamm Bowel Dis; 2017 Nov; 23(11):2027-2034. PubMed ID: 28817462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is fecal calprotectin an accurate marker in the management of Crohn's disease?
    Vernia F; Di Ruscio M; Stefanelli G; Viscido A; Frieri G; Latella G
    J Gastroenterol Hepatol; 2020 Mar; 35(3):390-400. PubMed ID: 31795013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease.
    Lobatón T; López-García A; Rodríguez-Moranta F; Ruiz A; Rodríguez L; Guardiola J
    J Crohns Colitis; 2013 Dec; 7(12):e641-51. PubMed ID: 23810085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
    Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
    Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
    Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
    World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Crohn's Disease.
    Ananthakrishnan AN; Adler J; Chachu KA; Nguyen NH; Siddique SM; Weiss JM; Sultan S; Velayos FS; Cohen BL; Singh S;
    Gastroenterology; 2023 Dec; 165(6):1367-1399. PubMed ID: 37981354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.